1. Healthcare

  2. •

    Medical - Instruments & Supplies
Invuity, Inc.

Invuity, Inc.

IVTY
Invuity, Inc.US flagNASDAQ
7.39
USD
- -
- -
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
0.91
1.95
2.76
2.18
2.32
2.14
Basic EPS, GAAP
-1.53
-3.07
-4.94
-2.73
-2.34
-1.91
Free Cash Flow per Basic Share
-1.81
-3.96
-4.59
-2.53
-2.33
-1.9
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-5.97
-10.11
-13.88
-9.83
-10.92
-10.8
Tangible Book Value per Share
-5.78
-9.78
5.57
2.32
-0.05
0.12
Basic Weighted Avg Shares
8
7
8
15
17
19
Sales/Revenue/Turnover
7
13
21
32
40
41
Operating Margin (%)
-166.37
-150.74
-167.41
-119.16
-89
-82.45
Depreciation Expense
- -
- -
2
2
2
2
Net Income, GAAP
-12
-21
-38
-41
-40
-36
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-168.51
-157.69
-178.64
-125.1
-100.75
-89.29
Working Capital
8
10
49
41
23
22
LT Debt
2
9
14
13
29
25
Total Equity
-46
-66
42
34
-1
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
ST Debt
6
4
10
LT Borrowings
29
29
25
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
24
24
Market Capitalization
106
67
75

Working Capital

FRC

•

in mil. unless spec.
Dec'17
Mar'18
Jun'18
Total Current Assets
37
49
41
Cash, Cash Equivalents & STI
21
33
24
Accounts Receivable, Net
7
6
7
Inventories
7
9
9
Total Current Liabilities
15
14
19
Payables & Accruals
9
10
5
ST Debt
6
4
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-102.5%
Free Cash Flow
- -
- -
5.49%
Net Income, GAAP
- -
- -
-1.7%
Sales/Revenue/Turnover
- -
- -
22.05%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
6
8
8
9
32
2017
9
10
10
11
40
2018
10
11
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-0.9
-0.76
-0.56
-0.56
-2.73
2017
-0.78
-0.61
-0.52
-0.43
-2.34
2018
-0.62
-0.37
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChat
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
IPO Date
Jun 15, 2015
CIK
0001393020
Similar Companies
Imeik Technology Development Co.,Ltd. (300896.SZ)
Micron Solutions, Inc. (MICRD)
SciVision Biotech Inc. (1786.TW)
Lancer Orthodontics, Inc. (LANZ)
DENTSPLY SIRONA Inc. (XRAY)
DENTSPLY SIRONA Inc. (0I8F.L)
Business
Invuity, Inc. develops and manufactures advanced medical surgical devices focused on enhanced visualization for surgical procedures. The company produces a range of products including single-use and reusable illuminated surgical devices such as soft tissue retractors, retractor systems, and lighting systems that employ intelligent photonics technology. These devices are designed to improve surgical precision and efficiency by providing illumination and direct visualization within surgical cavities, serving specialties including orthopedics, spine surgery, general surgery, and women's health. Invuity primarily operates in the United States and is headquartered in San Francisco, California, with its origins dating back to 2004. The company operates as a wholly-owned subsidiary of Stryker Corporation, following its acquisition by Stryker in 2018 for approximately $190 million. This acquisition allowed Invuity to leverage Stryker's sales and marketing infrastructure while continuing to develop and commercialize its portfolio of advanced photonics and single-use lighted instruments. Recent product innovations include enhancements to their illuminated retractor systems, such as the Eikon LT platform featuring atraumatic tissue grip, which expands the usability and safety profile of their devices in various surgical applications. Invuity continues to focus on growth and expanding commercial reach under Stryker's strategic framework, maintaining a strong emphasis on innovation in surgical visualization technology.